OA11957A - Metalloprotease inhibitors. - Google Patents

Metalloprotease inhibitors. Download PDF

Info

Publication number
OA11957A
OA11957A OA1200100319A OA1200100319A OA11957A OA 11957 A OA11957 A OA 11957A OA 1200100319 A OA1200100319 A OA 1200100319A OA 1200100319 A OA1200100319 A OA 1200100319A OA 11957 A OA11957 A OA 11957A
Authority
OA
OAPI
Prior art keywords
methylphenyl
piperidin
compound
methyl
préparation
Prior art date
Application number
OA1200100319A
Other languages
English (en)
Inventor
Kevin Neil Dack
Michael Jonathan Fray
Mark Liewellyn Lewis
Nicholas Murray Thomson
Gavin Alistair Whitlock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA11957A publication Critical patent/OA11957A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (39)

172 119 5 7 CLAIMS 1. N-Hydroxy 4-{[4-(4-{6-[2-hydroxyethoxy]pyridin-2-yl]-3-methylphenyI)piperidin-l-yl]sulphonyl]tetrahydro-2H-pyran-4-carboxamide and the pharmaceutically acceptablesalts thereof, and solvatés thereof.
2. A compound selected from : N-hydroxy 2-[(4- {4-[6-(2-hydroxyethoxy)pyridin-2-yl]-3-methylphenyl]piperidin-l -yl)sulphonyl]-2-methylpropanamide; N-hydroxy 2-{[4-(4-{6-[2-(methoxy)ethoxy]pyridin-2-yl}-3-methylphenyl)piperidin-l-yl]sulphonyl]-2-methylpropanamide; N-hydroxy 4- {[4-(4- {6-[2-hydroxyethoxy]pyridin-2-yl} -3-methylphenyl)piperidin-1 -yl] sulphonyl} tetrahydro-2H-pyran-4-carboxamide; N-hydroxy 4-{[4-(4-{6-[(2S)-2,3-dihydroxy-l-propoxy]pyridin-2-yl}-3-methylphenyl)piperidin-1 -yl] sulphonyl} tetrahydro-2H-pyran-4-carboxamide;N-hydroxy 4- {[4-(4- {6-[(2R)-2,3-dihydroxy-1 -propoxy]pyridin-2-yl} -3-methylphenyl)piperidin-1 -yl] sulphonyl} tetrahydro-2H-pyran-4-carboxamide;N-hydroxy 4- {[4-(4- {6- [2-hydroxyethoxy]pyridin-2-yl} -3 -methylphenyl)piperidin-1 -yl] sulphonyl} -piperidine-4-carboxamide dihydrochloride; N-hydroxy 4- {[4-(4- {6-[2-hydroxyethoxy]pyridin-2-yl}-3-methylphenyl)piperidin-l-yl]sulphonyl} -1 -methyl-piperidine-4-carboxamide; N-hydroxy 2- [4-(4- {3 - [ (2S)-2,3 -dihydroxy-1 -propoxy]phenyl} -3 -methylphenyl)-piperidin-1 -ylsulphonyl] -2-methylpropanamide; N-hydroxy 4-{4-[4-(3-[(2R)-2,3-dihydroxy-l-propoxy]phenyl)-3-methylphenyl]-piperidin-1 -ylsulphonyl} -tetrahydro-(2H)-pyran-4-carboxamide; N-hydroxy 4- {4-[4-(3- {(2S)-2-hydroxy-2-hydroxymethyl]ethoxyphenyl)-3-methylphenyl] -piperidin-1 -ylsulphonyl} -tetrahydro-2H-pyran-4-carboxamide;N-hydroxy 4-{4-[4-(3-{l,3-dihydroxy-2-propoxyphenyl)-3-methylphenyl]-piperidin-l-ylsulphonyl} -tetrahydro-2H-pyran-4-carboxamide; N-hydroxy 2- {[4-(4- {3-[2-(methylamino)ethoxy]phenyl} -3-methylphenyl)-piperidin-l -yl] sulphonyl]-2-methylpropanamide hydrochloride; H3 H957 N-hydroxy 2-(4-(4- {3-(2-aminoethoxy)phenyl} -3-methylphenyl)-piperidin-1 -ylsulphonyl]-2-methylpropanamide hydrochloride; N-Hydroxy 4- {[4-(-4- {3-[2-anrinoethoxy]phenyl}-3-rnethylphenyl)piperidin-l -yl]sulphonyl} tetrahydro-2H-pyran-4-carboxamide hydrochloride; N-hydroxy 2-(4-(4- {3-(2-N,N-dimethylaminoethoxy)phenyl} -3-methylphenyl)-piperidin-l-ylsulphonyl]-2-methylpropanamide; N-Hydroxy 4-{[4-(4-{3-(N-methylaminomethyl)phenyl}-3-methylphenyl)piperidin-l-yl]sulphonyl} tetrahydro-2H-pyran-4-carboxamide hydrochloride; N-hydroxy 4- {[4-(3-methyl-4- {3-[4-morpholinylmethyl]}phenyl)piperidin-1 -yl]sulphonyl}tetrahydro-2H-pyran-4-carboxamide; N-hydroxy 2-( {4-[4-(3-methoxy-1 H-pyrazol-1 -yl)-3-methylphenyl]piperidin-1 -yl}sulphonyl)-2-methylpropanamide; N-hydroxy 2-[(4-{4-[3-(2-hydroxyethoxy)-lH-pyrazol-l-yl]-3-methylphenyl}piperidin- l-yl)sulphonyl)-2-methylpropanamide; N-hydroxy 2-methyl-2-( {4-[3-methyl-4-( 1,3-thiazol-2-yl)phenyl]piperidin-1 -yl} sulphonyl)propanamide; (la,3a,4a)-Ar,3,4-trihydroxy-l-[(4-{4-[6-(2-hydroxyethoxy)pyridin-2-yl]-3- methylphenyl}piperidin-l-yl)sulfonyl]cyclopentanecarboxamide; (1 a, 3a,4a)-1 -( {4-[4-(6-ethoxypyridin-2-yl)-3-methylphenyl]piperidin-1 -yl} sulfonyl)-7V,3,4-trihydroxycyclopentanecarboxamide; (1 α,3β,4β)-1 -( {4-[4-(6-ethoxypyridin-2-yl)-3-methylphenyl]piperidin-l -yl} sulfonyl)-7V,3,4-trihydroxycyclopentanecarboxamide; ( 1 a,3a,4a)-N,3,4-trihydroxy-1 - {4-(4-(3 -methoxyphenyl)-3 -methylphenyljpip eridin-1 -ylsulfonyl} cyclopentanecarboxamide; and (1 a,3 β,4β)-Λζ3,4-trihydroxy-1 - {4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-l -ylsulfonyl} cyclopentanecarboxamide, and the pharmaceutically acceptable salts thereof, and solvatés thereof.
3. N-Hydroxy 4- {[4-(4- {6-[2-hydroxyethoxy]pyridin-2-yl} -3-methylphenyl)piperidin-1 - yl]sulphonyl}-piperidine-4-carboxamide and the pharmaceutically acceptable salts thereof, and solvatés thereof. 174 ”957
4. N-Hydroxy 4-{[4-(-4-{6-[2-aminoethoxy]pyridin-2-yl}-3-methylphenyl)piperidin-l-yl]sulphonyl}tetrahydro-2H-pyran-4-carboxamide and the pharmaceutically acceptablesalts thereof, and solvatés thereof.
5 wherein R3, X and R are as defined in any one of daims 5,6 or 7, Rp is as defined indaim 31, and P and P1 are OH-protecting groups which may be taken independently ortogether.
5. A compound of formula (I):
and pharmaceutically-acceptable salts thereof, and solvatés thereof,wherein 10 the dotted line represents an optional bond; X is a monocyclic aromatic linker moiety selected ffom pyrazolylene, thiazolylene,pyrazinylene, pyridazinylene, pyrrolylene, oxazolylene, isoxazolylene, oxadiazolylene,thiadiazolylene, imidazolylene, triazolylene, or tetrazolylene; R is H, Ci-4 alkyl optionally substituted by Cm alkoxy or NR4R5 or OH, or 15 Cm alkoxy optionally substituted by 1 or 2 substituents selected from (Cm alkyloptionally substituted by OH), Cm alkoxy, OH and NR4R5; R1 and R2 are each independently H, Cm alkyl optionally substituted by OH or Cmalkoxy, or C2-6 alkenyl; 20 or R1 and R2 are taken, together with the C atom to which they are attached, to form a β-ίο 7-membered ring optionally incorporating a hetero- moiety selected ffom O, S, SO,SO2 and NR6, and which 3- to 7-membered ring is optionally substituted by one or moreOH; R3 is H, halo, methyl, or methoxy; doi 173 ί î 9 5 7 R4 and R5 are each independently H or Ci to C6 alkyl optionally substituted by OH, Cito C4 alkoxy or aryl, or R4 and R5 can be taken together with the N atom to which they are attached, to forma 3- to 7-membered ring, optionally incorporating a further hetero- moiety selected from 5 O, S, SQ2 and NR7; and R6 and R7 are each independently H or Ci to C4 alkyl.
6. A compound of formula (I):
7. A compound of formula (I):
and pharmaceutically-acceptable salts thereof, and solvatés thereof,wherein 15 the dotted line represents an optional bond, X is a monocyclic aromatic linker moiety selected from phenylene, pyridinylene,pyrazolylene, thiazolylene, thienylene, furylene, pyrimidinylene, pyrazinylene,pyridazinylene, pyrrolylene, oxazolylene, isoxazolylene, oxadiazolylene,thiadiazolylene, imidazolylene, triazolylene, or tetrazolylene; 20 R is H, Cm alkyl optionally substituted by Cm alkoxy, NR4R5 or OH, or Cm alkoxy optionally substituted by 1 or 2 substituents selected from (Cm alkyloptionally substituted by OH), Cm alkoxy, OH and NR4R5; R1 and R2 are each independently Cm alkyl substituted by OH; m H 9 5 7 or R1 and R2 are taken together, with the C atom to which they are attached, to form a 3-to 7-membered ring optionally incorporating a hetero- moiety selected from O, S, SO,SO2 and NR6, and which 3- to 7-membered ring is substituted by one or more OH; R3 is H, halo, methyl, or methoxy; R4 and R5 are each independently H or Ci to Cô alkyl optionally substituted by OH, Cito C4 alkoxy or aryl, or R4 and R5 can be taken together with the N atom to which they are attached , to forma 3- to 7-membered ring, optionally incorporating a further hetero- moiety selected fromO, S, SO2 and NR7, and R6 and R7 are each independently H or Ci to C4 alkyl.
8. A compound, sait or solvaté according to claim 6 or claim 7 where X is phenylene,pyridinylene, pyrazolylene or thiazolylene.
9. A compound, sait or solvaté according to claim 8 wherein X is 1,3-phenylene, 2,6-pyridinylene, 1,3-pyrazolylene or 2,5-thiazolylene.
10. A compound, sait or solvaté according to claim 5 wherein X is pyrazolylene orthiazolylene.
10 and pharmaceutically-acceptable salts thereof, and solvatés thereof,wherein the dotted line represents an optional bond; X is a monocyclic aromatic linker moiety selected from phenylene, pyridinylene,pyrazolylene, thiazolylene, thienylene, furylene, pyrimidinylene, pyrazinylene, 15 pyridazinylene, pyrrolylene, oxazolylene, isoxazolylene, oxadiazolylene,thiadiazolylene, imidazolylene, triazolylene, or tetrazolylene; R is Cm alkyl substituted by NR4R5, Cm alkoxy substituted by NR4R5, or Ci .4 alkoxysubstituted by 2 substituents selected from (Cm alkyl optionally substituted by OH), Ci4 alkoxy, OH and NR4R5; 20 R1 and R2 are each independently H, Cm alkyl optionally substituted by OH or Cmalkoxy, orC2-6 alkenyl; or R1 and R2 are taken together, with the C atom to which they are attached, to form a 3to 7-membered ring optionally incorporating a hetero- moiety selected from O, S, SO, 11957 SOz and NR6, and which 3- to 7-membered ring is optionally substituted by one or moreOH; R3 is H, halo, methyl, or methoxy; R4 and R5 are each independently H or Cj to Cô alkyl optionally substituted by OH, Ci5 to C4 alkoxy or aryl, or R4 and R5 can be taken together with the N atom to which they are attached, to foraia 3- to 7-membered ring, optionally incorporating a further hetero- moiety selected fromO, S, SO2 andNR7, and R6 and R7 are each independently H or Ci to C4 alkyl. 0
11. A compound, sait or solvaté according to claim 10 wherein X is 1,3-pyrazolylene or 2,5-thiazolylene.
12. A compound, sait or solvaté according to claim 5 or claim 7 wherein R is H,methoxy, O(CH2)2OH, O(CH2)2OCH3, O(CH2)2N(CH3)2, O(CH2)2NHCH3,O(CH2)2NH2, CH2NHCH3, morpholinomethyl, 2-morpholinoethoxy, 2R-2,3-dihydroxy- 1-propyloxy, 2S-2,3-dihydroxy-l-propyloxy or l,3-dihydroxy-2-propyloxy.
13. A compound, sait or solvaté according to claim 12 wherein R is 0(CH2)2OH orO(CH2)2NH2. 178 119 5 7
14. A compound, sait or solvaté according to claim 6 wherein R is O(CH2)2N(CH3)2,O(CH2)2NHCH3, O(CH2)2NH2, CH2NHCH3, morpholinomethyl, 2-morpholinoethoxy,2R-2,3-dihydroxy-l-propyloxy, 2S-2,3-dihydroxy-l-propyloxy or l,3-dihydroxy-2-propyloxy. 5
15. A compound, sait or solvaté according to claim 14 wherein R is O(CH2)2NH2.
16.. A compound, sait or solvaté according to claim 5 or claim 6 wherein R1 and R2 areeach independently C1-6 alkyl optionally substituted by OH, 10 or R1 and R2 are taken together, with the C atom to which they are attached, to form a 3-to 7-membered ring optionally incorporating a hetero- moiety selected frorn O, S, SO,SO2 and NRb, and which 3- to 7-membered ring is optionally substituted by one or moreOH. 15
17. A compound, sait or solvaté according to claim 16 wherein R1 and R2 are each CH3, 1 2 or R and R are taken together, with the C atom to which they are attached, to form atetrahydropyran-4-ylidene, piperidin-4-ylidene, l-methylpiperidin-4-ylidene, or 3,4-dihydroxycyclopentylidene moiety. 20
18. A compound, sait or solvaté according to claim 17 wherein R1 and R2 are taken together, with the C atom to which they are attached, to form a tetrahydropyran-4-ylidene, cz's-3,4-dihydroxycyclopentylidene, Zrazw-3,4-dihydroxycyclopentylidene orpiperidin-4-ylidene moiety. 25
19. A compound, sait or solvaté according to claim 18 wherein R1 and R2 are taken together, with the C atom to which they are attached, to form a tetrahydropyran-4-ylidene, piperidin-4-ylidene, or cz's-3,4-dihydroxycyclopentylidene where the hydroxysubstituents hâve a czs-relationship to the hydroxamate moiety. ’OC i»ç 175 119 5 γ
20. A compound, sait or solvaté according to claim 7 wherein R1 and R2 are takentogether, with the C atom to which they are attached, to form a 3,4-dihydroxycyclopentylidene moiety.
21. A compound, sait or solvaté according to claim 20 wherein R1 and R2 are takentogether, with the C atom to which they are attached, to form a czs-3,4-dihydroxycyclopentylidene group where the hydroxy substituents hâve a cA-relationshipto the hydroxamate moiety.
22. A compound, sait or solvaté according to any one of daims 5 to 21 wherein R3 ismethyl and the optional double bond depicted as a dotted line in formula (I) is absent.
23. A pharmaceutical composition comprising a substance according to any one ofdaims 1 to 22 and a pharmaceutically acceptable diluent, adjuvant or carrier.
24. A substance according to any one of daims 1 to 22 for use as a médicament.
25. The use of a substance according to any one of daims 1 to 22 in the manufacture ofa médicament for the treatment of a MMP-mediated disease, condition or process.
26. A compound seiected from: methyl 4-(4-oxo-piperidin-1 -ylsulphonyl)tetrahydro-2H-pyran-4-carboxylate;methyl 4- {[4-(4-bromo-3-methylphenyl)-4-hydroxy-l-piperidin-l-yl]sulfonyl}tetrahydro-2/f-pyran-4-carboxylate; methyl 4- {[4-(4- {6-[2-(fôri-butoxy)ethoxy]pyridin-2-yl} -3-methylphenyl)piperidin-1 -yl]sulfonyl}tetrahydro-27/-pyran-4-carboxylate; 4- {[4-(4- {6-[2-tert-butoxyethoxy]pyridin-2-yl} -3-methylphenyl)piperidin-1 -yl]sulfonyl}-tetrahydro-2H-pyran-4-carboxylic acid; and A-hydroxy-4-[(4-{4-[6-(2-/erZ-butoxyethoxy)pyridin-2-yl]-3-methylphenyl}piperidin-l- yl)sulfonyl]tetrahydro-277-pyran-4-carboxamide. 1 19 5 7
27. A compound selected from: N-hydroxy 1 -(tert-butoxycarbonyl)-4- {[4-(4- {6-[2-hydroxyethoxy]pyridin-2-yl) -3-methylphenyl)piperidin-1 -yl] sulphonyl} -piperidine-4-carboxamide; 1 -(tert-butoxycarbonyl)- 4-[4-(4- {6-[2-hydroxyethoxy]pyridin-2-yl} -3- methylphenyl)piperidin-1 -ylsulphonyl]-piperidine-4-carboxylic acid; methyl 1 -(tert-butoxycarbonyl)- 4- {(4-(4- {6-[2-hydroxyethoxy]pyridin-2-yl} -3- methylphenyl)piperidin-1 -yl] sulphonyl) -4-piperidinecarboxylate; methyl 4- {(4-(4- {6-[2-hydroxyethoxy]pyridin-2-yl} -3-methylphenyl)piperidin-l - yl ]sulphonyl} -piperidine-4-carboxylate; methyl 1 -benzyl-4- {[4-(4- {6-[2-benzyloxyethoxy]pyridin-2-yl}-3- methylphenyl)piperidin-l-yl]suIphonyl}-piperidin-4-carboxylate; methyl 1 -benzyl-4-[4-(4-bromo-3-methylphenyl)piperidin-1 -ylsulphonyl] -4-piperidinecarboxylate; and methyl 2-[4-(4-bromo-3-methylphenyl)piperidin-1 -ylsulphonyl] acetate.
28. A compound selected from: N-hydroxy 4-(4-(4-{3-(2-[(N-tert-butoxycarbonyl)amino]ethoxy)phenyl}-3-methylphenyl)-piperidin-1 -ylsulphonyl] -tetrahydro-2H-pyran-4-carboxamide; N-hydroxy 4-(4-(4- {3-(2-[(tert-butoxycarbonyl)amino]ethoxy)phenyl} -3-methylphenyl)-piperidin-1 -ylsulphonyl] -tetrahydro-2H-pyran-4-carboxylate; methyl 4-(4-(4- {3-(2-((tert-butoxycarbonyl)amino]ethoxy)phenyl} -3-methylphenyl)- piperidin-1 -ylsulphonyl]-tetrahydro-2H-pyran-4-carboxylate; methyl 4-(4-(4-{3-(2-aminoethoxy)phenyl)-3-methylphenyl)-piperidin-l-ylsulphonyl]- tetrahydro-2H-pyran-4-carboxylate; methyl 4-(4-(4- {3-(2-(N-benzylamino]ethoxy)phenyl}-3-methylphenyl)-piperidin-l-ylsulphonyl]-tetrahydro-2H-pyran-4-carboxylate; methyl 4-(4-(4- {3-(2-oxoethoxy)phenyl}-3-methylphenyl)-piperidin-l-ylsulphonyl]-tetrahydro-2H-pyran-4-carboxylate; and methyl 4-(4-(4- (3-(2,2-diethoxyethoxy)phenyl) -3-methylphenyl)-piperidin-l -ylsulphonyl]-tetrahydro-2H-pyran-4-carboxylate. tet 119 5 7
29. A compound selected from: 4-[4-(4- {6-[2-hydroxyethoxy]pyridin-2-yl} -3-methylphenyl)piperidin-1 -ylsulphonyl]tetrahydro-2H-pyran-4-carboxylic acid; methyl 4- {[4-(4- {6-[2-hydroxyethoxy]pyridin-2-yl} -3-methylphenyl)piperidin-1 -5 yl]sulphonyl} tetrahydro-2H-pyran-4-carboxylate; methyl 4-[4-(4- {6-[2-benzyloxy]ethoxypyridin-2-yl} -3-methylphenyl)-1,2,3,6-tetrahydropyridin-1 -ylsulphonyl]tetrahydro-2H-pyran-4-carboxylate; andmethyl 4-[4-(4-bromo-3 -methylphenyl)-1,2,3,6-tetrahydropyridin-1 -ylsulphonyl]tetrahydro-2H-pyran-4-carboxylate. 10
30. A compound of formula (VI):
(VI) 15 wherein the substituents R1, R2, R3, X and R are as defined above in relation to any oneof claims 5, 6 or 7.
31. A compound of formula (VH): - 5 HONH
(VII) _ ι 119 5 7 wherein R1, R2, R3 and X are as defined in any one of daims 5,6 or 7, and where Rp is aNH- and/or OH-protected version of the corresponding compound of formula (I) asdefined in any one of daims 5, 6 or 7, and Avhere the corresponding compound of 5 formula (I) as defined in any one of daims 5,6 or 7 contains a free NH, NH2 or OHgroup.
32. A process for making a compound of formula (I) as defined in any one of daims 5, 6or 7 where R contains a free NH, NH2 or OH group, which comprises deprotecting a 10 corresponding compound of formula (VIT) as defined in daim 31.
33. A compound of formula (VUI) or (IX):
where R3, X and R are as defined in any one of daims 5, 6 or 7. 119 5 7
34. A compound of formula (X) or (XI) :
35. A compound of formula (ΧΠ): 10 HONH
R (XII) 184 119 5 7 wherein R3, X and R are as defined in any one of daims 5, 6 or 7 and Rlp and R2p is aN- and/or O-protected precursor which, on deprotection would give a correspondingcompound of formula (I) as defined in the corresponding claim 5,6 or 7. 5
36. A process for making a compound of formula (I) as defined in any one of daims 5,6 or 7 where R1 and/or R2 contains a ffee NH, NH2 or OH group, which comprisesdeprotecting a corresponding compound of formula (XH) as defined in claim 35.
37. A compound of formula (H) :
(H) 12 3 where R , R , R , X and R are as defined in any one of daims 5,6 or 7, and where Z is aleaving group such as chloro, bromo, iodo, C1.3 alkyloxy or HO. 15
38. A process for making a compound of formula (I) as defined in any one of daims 5, 6or 7, which comprises reaction of a compound of formula (Π) as defined in claim 37with hydroxylamine. 20
39. A compound of formula (ΧΙΠ): <iof
wherein R3, X and R are as defined in any one of daims 5, 6 or 7 and RIp, R2p and Rpare independently a N- and/or O-protected precursor which, on deprotection would givea corresponding compound of formula (I) as defined in the corresponding daims 5, 6 or 5 7 where R1, R2 and R contain a free NH, NH2 and/or OH group.
OA1200100319A 1999-06-03 2000-05-18 Metalloprotease inhibitors. OA11957A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9912961.1A GB9912961D0 (en) 1999-06-03 1999-06-03 Metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
OA11957A true OA11957A (en) 2006-04-17

Family

ID=10854704

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100319A OA11957A (en) 1999-06-03 2000-05-18 Metalloprotease inhibitors.

Country Status (42)

Country Link
EP (1) EP1181017B1 (fr)
JP (1) JP2003501388A (fr)
KR (1) KR20020006546A (fr)
CN (1) CN1365281A (fr)
AP (1) AP2001002348A0 (fr)
AR (1) AR028833A1 (fr)
AT (1) ATE237329T1 (fr)
AU (1) AU4601800A (fr)
BG (1) BG106242A (fr)
BR (1) BR0011130A (fr)
CA (1) CA2375882A1 (fr)
CO (1) CO5160324A1 (fr)
CZ (1) CZ20014262A3 (fr)
DE (1) DE60002193T2 (fr)
DK (1) DK1181017T3 (fr)
DZ (1) DZ3052A1 (fr)
EA (1) EA200101166A1 (fr)
EE (1) EE200100657A (fr)
ES (1) ES2193076T3 (fr)
GB (1) GB9912961D0 (fr)
GT (1) GT200000088A (fr)
HK (1) HK1049118A1 (fr)
HU (1) HUP0201633A3 (fr)
IL (1) IL146518A0 (fr)
IS (1) IS6164A (fr)
MA (1) MA26743A1 (fr)
MX (1) MXPA01012450A (fr)
NO (1) NO20015900L (fr)
NZ (1) NZ515458A (fr)
OA (1) OA11957A (fr)
PA (1) PA8496301A1 (fr)
PE (1) PE20010206A1 (fr)
PL (1) PL352829A1 (fr)
PT (1) PT1181017E (fr)
SK (1) SK17312001A3 (fr)
SV (1) SV2002000097A (fr)
TN (1) TNSN00121A1 (fr)
TR (1) TR200103493T2 (fr)
TW (1) TW529952B (fr)
UY (1) UY26186A1 (fr)
WO (1) WO2000074681A1 (fr)
ZA (1) ZA200109890B (fr)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
AU2003221786A1 (en) 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
US20050209278A1 (en) * 2002-04-25 2005-09-22 Mcdonald Joseph J Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
WO2005012326A1 (fr) 2003-08-01 2005-02-10 Tanabe Seiyaku Co., Ltd. Nouveaux composes possedant une activite inhibitrice dirigee contre le transporteur dependant du sodium
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US7897624B2 (en) 2006-04-18 2011-03-01 Ardea Biosciences Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
AU2008206045A1 (en) 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of MEK
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
NZ600110A (en) 2007-09-10 2013-03-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
ES2586032T3 (es) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
EP2401614A1 (fr) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2454267A2 (fr) 2009-07-16 2012-05-23 Royal College of Surgeons in Ireland Complexes métalliques ayant une double activité inhibitrice d'histone désacétylase et de liaison à l'adn
US9034861B2 (en) 2009-10-13 2015-05-19 Allomek Therapeutics Llc MEK inhibitors useful in the treatment of diseases
PH12012500698A1 (en) 2009-10-14 2016-05-27 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
WO2012116040A1 (fr) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
CN103596944B (zh) 2011-04-13 2017-02-22 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
CN103796656A (zh) 2011-06-14 2014-05-14 哈尔生物药投资有限责任公司 苯二氮卓的投与
WO2014062838A2 (fr) 2012-10-16 2014-04-24 Tolero Pharmaceuticals, Inc. Modulateurs de pkm2 et procédés pour les utiliser
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JP6621477B2 (ja) 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
EP3356347A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
EP3356353A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
NZ754994A (en) 2016-12-22 2022-12-23 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (fr) 2017-01-26 2018-08-02 Araxes Pharma Llc Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation
WO2018140600A1 (fr) 2017-01-26 2018-08-02 Araxes Pharma Llc Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation
EP3573971A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
EP3573954A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
KR20200010306A (ko) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
WO2018218069A1 (fr) 2017-05-25 2018-11-29 Araxes Pharma Llc Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants
WO2018226976A1 (fr) 2017-06-08 2018-12-13 Kura Oncology, Inc. Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
WO2019060365A1 (fr) 2017-09-20 2019-03-28 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
CN108285409B (zh) * 2018-03-07 2022-03-15 徐州博康信息化学品有限公司 一种合成叔丁氧基取代的苯乙烯及其衍生物的方法
CA3099118A1 (fr) 2018-05-04 2019-11-07 Amgen Inc. Inhibiteurs de kras g12c et leurs procedes d'utilisation
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3790886B1 (fr) 2018-05-10 2024-06-26 Amgen Inc. Inhibiteurs du kras g12c pour le traitement du cancer
EP3802535B1 (fr) 2018-06-01 2022-12-14 Amgen, Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
CA3099799A1 (fr) 2018-06-11 2019-12-19 Amgen Inc. Inhibiteurs de kras g12c pour le traitement du cancer
MA51848A (fr) 2018-06-12 2021-04-21 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3107168A1 (fr) 2018-08-01 2020-02-06 Araxes Pharma Llc Composes heterocycliques spiro et procedes d'utilisation correspondants pour le traitement du cancer
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
EA202191730A1 (ru) 2018-12-20 2021-08-24 Эмджен Инк. Ингибиторы kif18a
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
KR20210146287A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
WO2020198077A1 (fr) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
EP3738593A1 (fr) 2019-05-14 2020-11-18 Amgen, Inc Dosage d'inhibiteur de kras pour le traitement de cancers
EP3972973A1 (fr) 2019-05-21 2022-03-30 Amgen Inc. Formes à l'état solide
CN110483341A (zh) * 2019-07-23 2019-11-22 上海药明康德新药开发有限公司 一种1-氰基-n-甲基甲磺酰胺的合成方法
CN114391012B (zh) 2019-08-02 2025-10-31 美国安进公司 作为kif18a抑制剂的吡啶衍生物
WO2021026098A1 (fr) 2019-08-02 2021-02-11 Amgen Inc. Inhibiteurs de kif18a
ES3051918T3 (en) 2019-08-02 2025-12-30 Amgen Inc Kif18a inhibitors
JP7640521B2 (ja) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
WO2021055728A1 (fr) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Inhibiteurs à petites molécules de mutant de kras g12c
EP4048671B1 (fr) 2019-10-24 2026-03-18 Amgen Inc. Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
CR20220230A (es) 2019-10-28 2022-06-15 Merck Sharp & Dohme Inhibidores de pequeñas moléculas de mutante g12c de kras
WO2021085653A1 (fr) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. Dérivés de 4-aminobut-2-enamide et sels de ces derniers
EP4054719B1 (fr) 2019-11-04 2026-02-11 Revolution Medicines, Inc. Inhibiteurs de ras
KR20220109407A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
JP7823816B2 (ja) 2019-11-04 2026-03-04 レヴォリューション・メディスンズ，インコーポレイテッド Ｒａｓ阻害剤
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
WO2021097207A1 (fr) 2019-11-14 2021-05-20 Amgen Inc. Synthèse améliorée de composés inhibiteurs de kras g12c
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
WO2021108683A1 (fr) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
WO2021106231A1 (fr) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. Composé ayant une activité inhibitrice contre la mutation kras g12d
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
WO2021215545A1 (fr) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Polythérapie anticancéreuse avec un inhibiteur de n-(1-acryloyl-azétidin-3-yl)-2-((1h-indazol-3-yl) amino) méthyl)-1 h-imidazole-5-carboxamide de kras-g12c
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
CA3183032A1 (fr) 2020-06-18 2021-12-23 Mallika Singh Methodes de retardement, de prevention et de traitement de la resistance acquise aux inhibiteurs de ras
CN116113406B (zh) 2020-07-10 2025-08-29 密歇根大学董事会 Gas41抑制剂及其使用方法
EP4183395A4 (fr) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. Combinaison contenant un composé pyrimidine destinée à être utilisée dans le traitement de tumeurs
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
WO2022235866A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
CN117769554A (zh) 2021-05-28 2024-03-26 大鹏药品工业株式会社 Kras突变蛋白的小分子抑制剂
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023064058A1 (fr) 2021-10-12 2023-04-20 Peloton Therapeutics Inc. Sultames et sulfamides tricycliques utilisés en tant qu'agents antitumoraux
JP2025500878A (ja) 2021-12-17 2025-01-15 ジェンザイム・コーポレーション Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
EP4227307A1 (fr) 2022-02-11 2023-08-16 Genzyme Corporation Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2
IL314883A (en) 2022-03-07 2024-10-01 Amgen Inc A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques
PE20251879A1 (es) 2022-10-14 2025-07-22 Black Diamond Therapeutics Inc Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
CN116041251A (zh) * 2022-12-01 2023-05-02 温州大学 含卤原子的砜基四氢吡啶衍生物的合成方法
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
PE20260039A1 (es) 2023-04-07 2026-01-09 Revolution Medicines Inc Inhibidores macrociclicos de ras
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
WO2024226579A1 (fr) 2023-04-24 2024-10-31 Nested Therapeutics, Inc. Dérivé hétérocyclique utilisé comme inhibiteur de protéine kinase activée par les mitogènes (mek)
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202515582A (zh) 2023-08-24 2025-04-16 日商大塚製藥股份有限公司 西區嘧啶(cedazuridine)之固定劑量組合
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
ES2183905T3 (es) * 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
GB9725782D0 (en) * 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
KR20020006546A (ko) 2002-01-19
EP1181017A1 (fr) 2002-02-27
ES2193076T3 (es) 2003-11-01
ZA200109890B (en) 2003-02-26
TW529952B (en) 2003-05-01
HUP0201633A2 (en) 2002-08-28
GT200000088A (es) 2001-11-23
BR0011130A (pt) 2002-03-19
JP2003501388A (ja) 2003-01-14
AR028833A1 (es) 2003-05-28
TR200103493T2 (tr) 2002-04-22
EP1181017B1 (fr) 2003-04-16
TNSN00121A1 (fr) 2005-11-10
WO2000074681A1 (fr) 2000-12-14
SV2002000097A (es) 2002-07-16
IL146518A0 (en) 2002-07-25
ATE237329T1 (de) 2003-05-15
AP2001002348A0 (en) 2001-12-31
IS6164A (is) 2001-11-16
PL352829A1 (en) 2003-09-08
MA26743A1 (fr) 2004-12-20
UY26186A1 (es) 2000-12-29
SK17312001A3 (sk) 2003-03-04
NO20015900D0 (no) 2001-12-03
AU4601800A (en) 2000-12-28
GB9912961D0 (en) 1999-08-04
CO5160324A1 (es) 2002-05-30
EA200101166A1 (ru) 2002-06-27
DK1181017T3 (da) 2003-07-14
DZ3052A1 (fr) 2004-03-27
NZ515458A (en) 2002-12-20
HUP0201633A3 (en) 2004-03-01
CA2375882A1 (fr) 2000-12-14
NO20015900L (no) 2002-01-28
DE60002193D1 (de) 2003-05-22
EE200100657A (et) 2003-02-17
DE60002193T2 (de) 2003-10-16
PT1181017E (pt) 2003-06-30
CN1365281A (zh) 2002-08-21
MXPA01012450A (es) 2002-06-04
HK1049118A1 (zh) 2003-05-02
CZ20014262A3 (cs) 2003-01-15
PE20010206A1 (es) 2001-03-07
PA8496301A1 (es) 2002-02-21
BG106242A (en) 2002-08-30

Similar Documents

Publication Publication Date Title
OA11957A (en) Metalloprotease inhibitors.
US6511993B1 (en) Metalloprotease inhibitors
TWI344955B (en) Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
CA2753434C (fr) Activateurs solubles de guanylate cyclase
KR100936854B1 (ko) 옥시토신 길항제로서의 치환된 트리아졸 유도체
JP2021525219A (ja) がんに対する使用のための、ｅｇｆｒの分解を引き起こす化合物
KR20080027908A (ko) Ｇｐｃｒ 효능제
JP2005529161A (ja) ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン
EA015835B1 (ru) Производные 4-окса(тиа)метилпиперидина и их применение в качестве противодиабетических средств
HUT76275A (en) Cyclic amide derivatives, pharmaceutical compositions containing them and process for producing them
JP2002536373A (ja) スルファメトヒドロキサム酸メタロプロテアーゼ阻害剤
KR20070052693A (ko) 폴리헤테로시클릭 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도
CA2617654A1 (fr) Composes piperidinoyl-pyrrolidine et piperidinoyl-piperidine
JP2002504081A (ja) エンドセリン拮抗物質としての新規なベンゾ―１，３―ジオキソリル―及びベンゾフラニル置換ピロリジン誘導体
EP1716135B1 (fr) Piperidinyl-carbonyl-pyrrolidines et leur utilisation en tant que agonistes de la melanocortine
AU2003230923A1 (en) Melanocortin receptor ligands
US7649002B2 (en) (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
AU2006251329A1 (en) Substituted piperidines as renin inhibitors
CN101103002A (zh) 3,4(,5)-取代的四氢吡啶
KR20230083276A (ko) 오토탁신 억제제 화합물
JP2002504082A (ja) アレルギー疾患の治療に有用な新規な置換されたｎ―メチル―ｎ―（４―（ピペリジン―１―イル）―２―（アリール）ブチル）ベンズアミド
FR2756285A1 (fr) Derives de n-(imidazolylbutyle)benzenesulfonamide, leur preparation et leur application en therapeutique
HU211690A9 (hu) Az átmeneti oltalom az 1—18. igénypontokra vonatkozik.
HK1113927B (en) Substituted triazole derivatives as oxytocin antagonists